30 results about "Insulin mimetic" patented technology

The present invention relates to the compositions that enhance post-exercise recovery processes to increase both strength and muscle mass, replace glycogen stores, and prevent inflammation, resulting in the prevention and/or reduction of delayed onset muscle soreness. Additionally, it provides a feeling of muscle relaxation as well as a feeling of mental tranquility immediately following exercise. The composition consists of any or all high-glycemic sugars and/or polysaccharides (e.g., sucrose, glucose, maltodextrin), all essential amino acids and beta-hydroxy-beta-methylbutyrate and can include other amino acids sources (e.g. whey protein), performance enhancing agents (e.g., caffeine, L-glutamate), anti-inflammatory agents (e.g., ginger, boswellia, curcumen), antioxidants (vitamin C, vitamin E, selenium, polyphenols,), insulin-mimicking agents (cinnamon, Banaba), analgesics (e.g. aspirin, ibuprofen, naproxen, acetaminophen), and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof.

This invention provides reagents and methods for delivering insulin, insulinomimetic agents, and the like to a vertebrate eye via subconjunctival routes, sub-Tenon's routes, or intravitreal routes for treatment of nerve-related vision disorders such as diabetic retinopathy, and formulations useful in the practice of the disclosed methods.

Identification of the human insulin receptor binding site sequence of certain spatial molecular structures conforming to such binding site and of certain insulinomimetic sequences including the binding site sequence are disclosed.

The invention relates to an amino acid sequence of a fusion protein for treating human type I and type II diabetes, and a production method and an application thereof. The invention relates to a noninsulin diabetes treatment method which can be used for avoiding insulin resistance. The fusion protein related to the invention is formed by fusing an insulin mimetic peptide and an IgG-Fc or IgG-Fc mutant through a connecting peptide, so that the in-vivo half-life of the insulin mimetic peptide can be prolonged remarkably while the blood sugar lowering activity of the insulin mimetic peptide is kept. The mutant of IgG-Fc can be used for further prolonging the in-vivo half-life of the fusion protein.

Combinations comprising vanadium (IV)/(V) compounds and pharmaceutically acceptable amines selected from the group of semicarbazide-sensitive amine oxidase (SSAO) substrates are insulin mimickers. Preferred vanadium (IV)/(V) compounds are vanadyl salts, vanadyl complexes and vanadates (e.g. sodium orthovanadate). Preferred amines are tyramine and benzylamine. A here-discovered synergism between the vanadium compound and the amine makes the effective concentration of vanadate in the combination one order of magnitude lower than the corresponding of vanadate alone. Consequently the combination has much lower toxicity than the known vanadium compound alone, which is a crucial advantage of the former for its use in the treatment and/or prevention of Diabetes mellitus.

This invention provides a method of promoting bone healing by locally administering a vanadium-based insulin mimetic agent to a patient in need thereof. The invention also provides a new use of insulin-mimetic vanadium compounds for manufacture of medicaments for accelerating bone-healing processes. In addition, the invention also encompasses a bone injury treatment kit suitable for localized administration of insulin-mimetic vanadium compounds or compositions thereof to a patient in need of such treatment.

A therapeutic agent and prophylactic agent for a disease accompanying an abnormality in an amount of insulin or insulin response, an agent for an insulin-mimetic action, a food, beverage and feed, an agent for enhancing glucose uptake into a cell, and an agent for inducing differentiation into an adipocyte, characterized in that each comprises as an effective ingredient at least one compound selected from the group consisting of a chalcone compound, an acetophenone compound, a coumarin compound, a phthalide compound, derivatives thereof, and pharmacologically acceptable salts thereof.

The present invention discloses vanadium-based insulin-mimetic agent composite coatings, application of these coatings onto implantable devices, and use of the implantable devices for accelerating osseous healing. The invention also encompasses methods of manufacturing implantable devices coated with vanadium-based insulin-mimetic agent composite coatings and the implantable devices so manufactured. The implantable devices have wide applications, including but not limited to treating bone fracture, bone trauma, arthrodesis, and other bone deficit conditions, as well as bone injuries incurred in military and sports activities.

Shown and described is an insulin-mimetic as an inductive agent for cartilage and/or bone repair is disclosed. Sodium tungstate (Na₂WO₄) was utilized as an inductive factor to enhance human mesenchymal stem cell (MSC) chondrogenesis. The chondrogenic differentiation of MSCs was enhanced in the presence of low concentrations of Na₂WO₄ as compared to control, without Na₂WO₄. Also disclosed is a composite scaffold capable of supporting cell and tissue growth. The composite scaffold could include zinc oxide and polycaprolactone.

Methods of promoting bone healing or regeneration by locally administering insulin mimetic agents to patients in need thereof and new uses of insulin-mimetic compounds for accelerating bone-healing processes are disclosed. Bone injury treatment and void filler devices, products and kit suitable for local administration of insulin-mimetic agents or compositions thereof to patients in need of such treatment are also disclosed.

The present invention relates to a therapeutic agent and prophylactic agent for a disease accompanying an abnormality in an amount of insulin or insulin response, an agent for an insulin-mimetic action, a food, beverage and feed for treating a preventing a disease accompanying an abnormality in an amount of insulin or insulin response, an agent for enhancing glucose uptake into a cell, and an agent for inducing differentiation into an adipocyte, characterized in that each comprises as an effective ingredient a processed product derived from at least one plant selected from the group consisting of (a) a plant belonging to Tiliaceae, (b) a plant belonging to Zingiberaceae, (c) a plant belonging to Compositae, (d) a plant belonging to Liliaceae, and (e) a plant belonging to Polygonaceae.

A pharmaceutically acceptable peroxovanadium(v) amine product, DmpzH[VO(02)2](Dmpz)], and its oral as well as injectable use for the treatment of Diabetes mellitus, wherein the said therapeutically stable compound is obtained by reacting V205 or vanadate with hydrogen peroxide and the amine, dimethylpyrazole (Dmpz), at pH 5.5 and temperature 0-4° C. DmpzH[VO(02)2](Dmpz)] is thus poised as a versatile insulin mimic adapted for targeting insulin signaling, stimulating adipogenesis, abrogating insulin stimulated down stream signals thereby lowering the incidence of insulin resistance and type-2 diabetes.

The invention relates to three organic vanadium complexes with insulin mimetic activity, and preparation method thereof, and belongs to the technical field of complex synthesis and medicine chemistry.Vanadium ions are taken as the center ions of the three complexes. (E)-N'-(2-hydroxybenzylidene)-3-methoxybenzhydrazide and ethyl maltol are taken as the ligands of a complex 1; (E)-N'-(2-hydroxybenzylidene)-3, 5-dimethoxybenzoyl hydrazine and methanol are taken as the ligands of a complex 2; and (E)-N'-(3-ethoxy-2-hydroxybenzylidene)-3,5-dimethoxybenzhydrazide and ethyl maltol are taken as the ligands of a complex 3. The three complexes are of sole-core structures, and hexa-coordinate octahedral coordination configurations are adopted. It is found in tests that the complexes 1, 2, and 3 possess relatively high insulin mimetic activity, are capable of reducing blood sugar of type I diabetes Kunming mouse obviously, and can be used for preparing hypoglycemic drugs.

Methods are provided for identifying and selecting candidate molecules that activate glucose transport through binding of the insulin receptor at a site other than the insulin binding site. The methods include analyzing the properties of one or more candidate molecules in terms of the ability to bind the insulin receptor and activate glucose transport. Optionally the methods include, competitive assays in the presence of the glucose receptor, a candidate molecule, and one or more of insulin, alpha PGG and beta PGG.

The provided water-soluble polypeptide compound belonged to synthetic insulin mimetic peptide comprises nine amino acids of a and b types connected with each other by peptide bond, can combine with insulin antibody and specific the insulin acceptor in body to produce hypoglycemic effect to replace the insulin for diabetic treatment, and can be composed more easily than the double-bond insulin with low cost and high purity.

The invention belongs to the technical field of medicinal preparations, and discloses an insulin oral selenium nano preparation being capable of promoting the oral absorption of insulin and having the synergetic blood sugar decreasing effect of selenium, and a preparation method of the insulin oral selenium nano preparation. According to the preparation method, a selenium-containing reagent is added into a solution or suspension containing insulin and chitosan, and selenium/chitosan nanoparticles loaded with insulin are generated under the effect of a reducing agent. The insulin oral selenium nano preparation can be effectively loaded with insulin, so that insulin is efficiently loaded into the nanoparticles formed by chitosan and selenium, therefore, the release and exposure of insulin in the gastrointestinal tract after oral medication are reduced, thus the gastrointestinal tract stability of insulin is improved, the absorbability and biological activity of selenium are also improved, and finally, the bioavailability of insulin and selenium is improved. In addition, with the addition of selenium, the preparation has the effect of decreasing blood sugar level, meanwhile, the function of the body can be reconstructed through the oxidation resistance, blood sugar regulation and insulin-mimetic effect of selenium, the synergetic blood sugar decreasing effect is realized through the insulin-mimetic effect of selenium, and thus the function of treating both symptoms and root causes of diabetes is realized.

The present invention relates to a therapeutic agent or prophylactic agent for a disease accompanying an abnormality in an amount of insulin or insulin response, an insulin-mimetic action agent, a food, beverage, or feed, an agent for enhancement of glucose uptake into a cell, and an agent for inducing differentiation into an adipocyte, each comprising as an effective ingredient at least one compound selected from the group consisting of specified compounds having an insulin-mimetic action, derivatives thereof, and pharmacologically acceptable salts thereof.